Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junko S Takeuchi

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Scientific Reports|September 14, 2022
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal studyJunko S Takeuchi, Ami Fukunaga, Shohei Yamamoto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 24, 2021
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching StudyShohei Yamamoto, Kenji Maeda, Kouki Matsuda, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 24, 2023
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant waveShohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Plos Pathogens|October 21, 2014
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse modelKei Sato, Junko S Takeuchi, Naoko Misawa, et al.
Open Forum Infectious Diseases|September 25, 2024
Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Human Vaccines & Immunotherapeutics|April 13, 2023
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in JapanJunko Terada-Hirashima, Yuki Takamatsu, Yosuke Shimizu, et al.
Vaccines|April 23, 2022
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA VaccineSeik-Soon Khor, Yosuke Omae, Junko S Takeuchi, et al.
Scientific Reports|November 5, 2015
Coevolutionary dynamics between tribe Cercopithecini tetherins and their lentivirusesJunko S Takeuchi, Fengrong Ren, Rokusuke Yoshikawa, et al.
Journal of Hepatology|November 29, 2016
Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activitySatomi Shimura, Koichi Watashi, Kento Fukano, et al.
Journal of Virology|May 13, 2021
MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core PromoterMarwa K Ibrahim, Tawfeek H Abdelhafez, Junko S Takeuchi, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Scientific Reports|September 14, 2022
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal studyJunko S Takeuchi, Ami Fukunaga, Shohei Yamamoto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 24, 2021
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching StudyShohei Yamamoto, Kenji Maeda, Kouki Matsuda, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 24, 2023
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant waveShohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Plos Pathogens|October 21, 2014
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse modelKei Sato, Junko S Takeuchi, Naoko Misawa, et al.
Open Forum Infectious Diseases|September 25, 2024
Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Human Vaccines & Immunotherapeutics|April 13, 2023
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in JapanJunko Terada-Hirashima, Yuki Takamatsu, Yosuke Shimizu, et al.
Vaccines|April 23, 2022
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA VaccineSeik-Soon Khor, Yosuke Omae, Junko S Takeuchi, et al.
Scientific Reports|November 5, 2015
Coevolutionary dynamics between tribe Cercopithecini tetherins and their lentivirusesJunko S Takeuchi, Fengrong Ren, Rokusuke Yoshikawa, et al.
Journal of Hepatology|November 29, 2016
Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activitySatomi Shimura, Koichi Watashi, Kento Fukano, et al.
Journal of Virology|May 13, 2021
MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core PromoterMarwa K Ibrahim, Tawfeek H Abdelhafez, Junko S Takeuchi, et al.
Pageof 5